ZYX and bone cancer: First, through FRAP-experiments we examined the binding dynamics of fluorescently-labelled paxillin, vinculin, VASP and zyxin at FAs in two different cell-types from two different species; U2OS cells, a human bone cancer cell line, and MDCK dog kidney cells (Fig. 1).